# Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults

> **NCT01033877** · PHASE3 · COMPLETED · sponsor: **Statens Serum Institut** · enrollment: 802 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** TdaP vaccine SSI
- **BIOLOGICAL:** Td vaccine SSI

## Key facts

- **NCT ID:** NCT01033877
- **Lead sponsor:** Statens Serum Institut
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 802 (ACTUAL)
- **Last updated:** 2013-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01033877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01033877, "Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01033877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*